Compounded Semaglutide Safety: Quality, Testing, and Red Flags to Watch

Medical Disclaimer: The information on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any medication or peptide protocol. Compounded medications carry unique risks. See our full disclaimer for details.

Key Takeaways

• Compounded semaglutide is a copy of brand-name semaglutide (Wegovy/Ozempic) made by a licensed compounding pharmacy. It is not FDA-approved.
• The FDA allowed compounding during the Wegovy/Ozempic shortage period but has moved to end that exception. The regulatory situation is actively evolving.
• There are important differences between semaglutide salt forms: semaglutide base vs. semaglutide sodium vs. semaglutide acetate. These are not chemically equivalent.
• 503A pharmacies compound for individual patients with a valid prescription. 503B outsourcing facilities can produce larger batches and are subject to more oversight.
• Third-party testing (certificate of analysis) is the minimum standard for evaluating a compounding pharmacy.
• Hard red flags include no prescription requirement, prices far below market, no verifiable pharmacy license, and claims that their compound is equivalent to Wegovy.
• Contamination events and product recalls have occurred with compounded GLP-1 medications. Due diligence matters.

---

What Is Compounded Semaglutide?

Semaglutide is the active ingredient in the FDA-approved medications Wegovy (for weight management) and Ozempic (for type 2 diabetes). Novo Nordisk manufactures both under tightly controlled pharmaceutical conditions with years of safety and efficacy data behind them.

Compounded semaglutide is a version produced by a compounding pharmacy that mixes ingredients, including the active semaglutide compound, to create a product for dispensing. The end product is not FDA-approved. It has not undergone the clinical trial process required of brand-name pharmaceuticals.

Compounding has a legitimate medical purpose. Some patients have allergies to excipients in commercial products. Others need doses or delivery forms not available commercially. Compounded medications fill these gaps under the oversight of state pharmacy boards and, for outsourcing facilities, the FDA.

The issue with compounded semaglutide is scale. During the shortage of brand-name products from 2022 through 2024, thousands of compounding pharmacies and telehealth companies began offering compounded semaglutide to the general public. Quality varied enormously.

For an in-depth comparison of compounded vs. brand-name products, see our companion post: Compounded vs. Brand Name Semaglutide and Tirzepatide.

---

The FDA's Position

The FDA does not approve compounded drugs. It does, however, regulate certain compounding facilities and conditions under which compounding is legal.

During a shortage of an FDA-approved drug, compounding pharmacies may legally compound copies of that drug under specific conditions established by the Federal Food, Drug, and Cosmetic Act. The FDA placed both semaglutide and tirzepatide products on its drug shortage list, which opened the door for legal compounding at scale.

As of 2025 and into 2026, the FDA has moved to remove semaglutide from the shortage list, which changes the legal status of compounded versions. The FDA has issued warning letters to compounding facilities and telehealth companies for violations including:

• Compounding semaglutide without a valid patient-specific prescription
• Making false or misleading claims about equivalence to brand-name products
• Using unapproved salt forms
• Selling through non-pharmacy channels

The regulatory situation continues to evolve. Patients using compounded semaglutide should stay current with FDA guidance and work with a licensed provider who understands the legal landscape.

For the most current regulatory picture, see our FDA Peptide Regulations 2026 overview.

---

Salt Form Differences: This Matters More Than Most People Realize

One of the most important and least discussed issues in compounded semaglutide is the salt form used in the product.

FDA-approved Wegovy and Ozempic use semaglutide base as the active ingredient. The chemical identity, dosing, and pharmacokinetics of the approved drugs are all calibrated to this specific form.

Many compounding pharmacies use semaglutide sodium or semaglutide acetate instead. These are different chemical forms of semaglutide. They are not bioequivalent to the base form in a direct 1:1 ratio. The conversion factor is not standardized across compounders.

This creates a real dosing problem. A product labeled "semaglutide 2.4 mg" using the sodium or acetate salt contains a different amount of active semaglutide than 2.4 mg of the base form. The FDA has specifically cited this as a safety concern.

In a 2024 alert, the FDA warned that patients may receive inconsistent doses due to salt form differences. Overdoses are not theoretical. There have been reports of patients experiencing severe side effects, including hospitalizations, linked to improperly dosed compounded products.

What to ask: Find out specifically what form of semaglutide your compounding pharmacy uses and what the molecular weight conversion is. A pharmacy that cannot or will not answer this question is a concern.

---

503A vs. 503B: What the Designations Mean

Not all compounding pharmacies operate under the same regulatory framework. Understanding the difference matters for evaluating quality.

503A Pharmacies

503A is the designation for traditional compounding pharmacies. They compound for specific patients based on individual prescriptions from licensed practitioners. They are regulated primarily by state boards of pharmacy.

Key characteristics:

• Must have a valid patient-specific prescription
• Regulated at the state level, standards vary by state
• Not subject to FDA Current Good Manufacturing Practice (CGMP) requirements
• Cannot produce large batches for anticipated demand
• Quality control is the responsibility of the individual pharmacy

A 503A pharmacy is not inherently lower quality than a 503B facility. Many operate with rigorous internal standards. But the oversight framework is less stringent, and there is more variability across the category.

503B Outsourcing Facilities

503B outsourcing facilities registered with the FDA are held to higher standards. They can produce larger batches of compounded drugs without individual patient-specific prescriptions, but they are subject to FDA inspections and CGMP requirements.

Key characteristics:

• FDA-registered and subject to regular inspections
• Must comply with CGMP standards
• Can produce bulk batches and sell to healthcare facilities
• Required to report adverse events
• Higher regulatory bar than 503A

A 503B facility is generally the higher-assurance option for compounded semaglutide. That said, registration is not a guarantee of quality. The FDA has found violations at registered 503B facilities too. Verification is always necessary.

---

How to Evaluate a Compounding Pharmacy

Whether you are working with a 503A or 503B facility, these are the minimum standards to evaluate before using their product.

1. Verify the License

Every legitimate compounding pharmacy must hold a valid pharmacy license in the state where it operates. Verify this independently on your state board of pharmacy website. Do not rely on the pharmacy's own claims. The NABP (National Association of Boards of Pharmacy) also maintains a database of accredited pharmacies at nabp.pharmacy.

2. Ask for the Certificate of Analysis (COA)

A COA is a third-party lab report certifying the identity, potency, and purity of the compound. It should be issued by an independent testing laboratory, not the pharmacy's internal quality department.

A legitimate COA for compounded semaglutide will show:

• Confirmed identity of the active ingredient
• Measured potency (actual concentration vs. labeled concentration, within acceptable range)
• Sterility testing (for injectable products)
• Endotoxin testing (for injectable products)
• Absence of specified contaminants

If a pharmacy cannot provide a COA for their semaglutide product or provides one from an in-house lab only, that is a problem.

3. Confirm the Salt Form and Dose Calculation

Ask specifically: Is this semaglutide base, semaglutide sodium, or semaglutide acetate? If it is not the base form, ask how doses are calculated to account for the molecular weight difference. The answer should be specific and documented in their product specifications.

4. Verify the Prescription Requirement

Any pharmacy legally dispensing compounded semaglutide requires a valid prescription from a licensed healthcare provider. If a website allows you to purchase compounded semaglutide without a prescription or with a perfunctory checkbox that you fill out yourself without a real clinical encounter, that is not a legal operation. Do not use them.

5. Check for PCAB Accreditation

The Pharmacy Compounding Accreditation Board (PCAB) offers voluntary accreditation for compounding pharmacies that meet rigorous standards. PCAB-accredited pharmacies have undergone independent review of their processes, facilities, and quality systems. Accreditation is not required but is a positive signal.

---

Red Flags That Signal a Bad Actor

The compounded semaglutide market attracted bad actors during the shortage period. Some remain active. These are the clearest warning signs.

No prescription required. This is illegal for scheduled prescription compounds in all 50 states. Full stop.

Price far below market. Legitimate compounded semaglutide through a real physician-supervised program typically costs $200 to $500 per month. Offers of $50 to $100 per month for injectable semaglutide should raise questions about sourcing and quality.

Claims of equivalence to Wegovy or Ozempic. Compounded semaglutide is not FDA-approved. It is not equivalent to brand-name products in any regulatory sense. Pharmacies that claim their product is the same as Wegovy are making false statements.

No verifiable pharmacy license. Any legitimate compounding pharmacy will have a state pharmacy license number you can verify independently.

Vague sourcing. Active pharmaceutical ingredients used in compounding must come from FDA-registered manufacturers. If a pharmacy will not tell you where their semaglutide API comes from, or claims to source it internationally outside FDA oversight, that is a red flag.

No physician involvement or a fake clinical encounter. The prescription requirement exists for a reason. A legitimate telehealth program involves a real clinical evaluation. A checkbox questionnaire that automatically generates a prescription without actual physician review is not a real clinical encounter.

No adverse event reporting process. Legitimate pharmacies have a process for patients to report adverse events. If you cannot find this information, ask directly. The absence of a reporting mechanism is a quality concern.

---

Real Contamination Events

Compounded product recalls and safety events are not hypothetical. During 2023 and 2024, several contamination events and product quality failures were documented.

The FDA issued multiple warning letters and initiated recalls involving compounded GLP-1 medications for issues including:

• Microbial contamination in injectable products
• Incorrect potency (products testing significantly higher or lower than labeled concentration)
• Use of unapproved ingredients or excipients
• Improper sterile manufacturing conditions

These events underscore why third-party testing and regulatory verification matter. The compounded drug market is not uniformly dangerous, but it is not uniformly safe either.

---

What to Ask Your Provider

If you are considering or already using compounded semaglutide, these are the questions to raise with your prescribing provider:

1. What compounding pharmacy are you working with, and is it 503A or 503B?
2. Can I see the current COA for this product?
3. What salt form is used, and how are doses calculated?
4. Is the API sourced from an FDA-registered manufacturer?
5. Is there a clinical team I can contact if I experience side effects?
6. How are prescriptions renewed, and does someone review my progress?

A provider who cannot or will not answer these questions, or who dismisses them as unnecessary, is not providing adequate care oversight.

---

The Practical Position

Compounded semaglutide has provided access to an effective medication for patients who could not afford or obtain brand-name versions during the shortage period. That access has real value. It is not categorically unsafe when sourced from a rigorous, properly licensed pharmacy with documented quality controls.

But the space has significant quality variation. Patients who do not know the right questions to ask are at risk of receiving products that are improperly dosed, contaminated, or sourced outside legitimate supply chains.

The minimum bar: valid prescription, verifiable pharmacy license, documented third-party COA, clear salt form and dose documentation. If a source cannot clear all four of those hurdles, look elsewhere.

For a beginner's guide to starting on compounded semaglutide through a supervised protocol, see our Compounded Semaglutide and Tirzepatide Protocol for Beginners.

---

FAQ

Is compounded semaglutide FDA-approved? No. Compounded drugs are not FDA-approved, regardless of the pharmacy that makes them. The FDA approves specific drug products after reviewing safety and efficacy data. Compounded medications bypass that process.

Is 503B better than 503A for compounded semaglutide? 503B outsourcing facilities are subject to higher regulatory oversight including FDA inspections and CGMP requirements. They are generally the higher-assurance option. That said, a well-run 503A pharmacy with strong internal quality controls and third-party testing can still be a reliable source. Verify each facility individually.

What does a certificate of analysis (COA) tell me? A COA is a third-party lab report confirming the compound's identity, potency, sterility, and purity. It is the primary quality document for compounded injectables. Always ask for the most recent COA for the specific lot of product you are receiving.

What is the difference between semaglutide base, sodium, and acetate? These are different salt forms of the same molecule. They are not directly interchangeable at equal doses. FDA-approved products use semaglutide base. Compounders using sodium or acetate forms must adjust doses accordingly, and standardized conversion factors are not universal across the industry. This is a real dosing risk.

Can I buy compounded semaglutide without a prescription? Not legally. Any source selling compounded semaglutide without a valid prescription from a licensed healthcare provider is operating outside the law. Avoid these sources entirely.

---

Sources

1. FDA Drug Shortage Database: Semaglutide Injection. U.S. Food and Drug Administration. fda.gov/drugs
2. FDA. "Compounding and the FDA: Questions and Answers." U.S. Food and Drug Administration. 2023. fda.gov/drugs/human-drug-compounding
3. Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine. 2021. PMID: 33567185
4. FDA Warning Letters: GLP-1 Compounding Violations. 2023-2024. Archived at fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters
5. NABP. "Protect Yourself from Counterfeit Drugs: Verifying Pharmacy Licenses." National Association of Boards of Pharmacy. nabp.pharmacy.

---

This content is for informational purposes only. Not medical advice. See our full disclaimer.